These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 24359765

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Serial evaluation of electrocardiographic left ventricular hypertrophy for prediction of risk in hypertensive patients.
    Okin PM.
    J Electrocardiol; 2009; 42(6):584-8. PubMed ID: 19631946
    [Abstract] [Full Text] [Related]

  • 3. Clinical implications of electrocardiographic left ventricular strain and hypertrophy in asymptomatic patients with aortic stenosis: the Simvastatin and Ezetimibe in Aortic Stenosis study.
    Greve AM, Boman K, Gohlke-Baerwolf C, Kesäniemi YA, Nienaber C, Ray S, Egstrup K, Rossebø AB, Devereux RB, Køber L, Willenheimer R, Wachtell K.
    Circulation; 2012 Jan 17; 125(2):346-53. PubMed ID: 22147903
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Changes in electrocardiographic left ventricular hypertrophy and risk of major cardiovascular events in isolated systolic hypertension: the LIFE study.
    Larstorp AC, Okin PM, Devereux RB, Olsen MH, Ibsen H, Dahlöf B, Kjeldsen SE, Wachtell K.
    J Hum Hypertens; 2011 Mar 17; 25(3):178-85. PubMed ID: 20505749
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Electrocardiographic left ventricular hypertrophy in GUSTO IV ACS: an important risk marker of mortality in women.
    Westerhout CM, Lauer MS, James S, Fu Y, Wallentin L, Armstrong PW, GUSTO IV ACS Investigators.
    Eur Heart J; 2007 Sep 17; 28(17):2064-9. PubMed ID: 17600040
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Cardiovascular prognosis in patients with type 2 diabetes: contribution of heart and kidney subclinical damage.
    Sosner P, Hulin-Delmotte C, Saulnier PJ, Cabasson S, Gand E, Torremocha F, Piguel X, Miot A, Maréchaud R, Herpin D, Ragot S, Hadjadj S, SURDIAGENE Study Group.
    Am Heart J; 2015 Jan 17; 169(1):108-14.e7. PubMed ID: 25497255
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Prognostic value of changes in the electrocardiographic strain pattern during antihypertensive treatment: the Losartan Intervention for End-Point Reduction in Hypertension Study (LIFE).
    Okin PM, Oikarinen L, Viitasalo M, Toivonen L, Kjeldsen SE, Nieminen MS, Edelman JM, Dahlöf B, Devereux RB, LIFE Study Investigators.
    Circulation; 2009 Apr 14; 119(14):1883-91. PubMed ID: 19332468
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. CHADS₂, CHA₂S₂DS₂-VASc, and long-term stroke outcome in patients without atrial fibrillation.
    Ntaios G, Lip GY, Makaritsis K, Papavasileiou V, Vemmou A, Koroboki E, Savvari P, Manios E, Milionis H, Vemmos K.
    Neurology; 2013 Mar 12; 80(11):1009-17. PubMed ID: 23408865
    [Abstract] [Full Text] [Related]

  • 16. Prognosis in patients with atrial fibrillation and CHA2DS2-VASc Score = 0 in a community-based cohort study.
    Taillandier S, Olesen JB, Clémenty N, Lagrenade I, Babuty D, Lip GY, Fauchier L.
    J Cardiovasc Electrophysiol; 2012 Jul 12; 23(7):708-13. PubMed ID: 22268375
    [Abstract] [Full Text] [Related]

  • 17. Does chronic kidney disease improve the predictive value of the CHADS2 and CHA2DS2-VASc stroke stratification risk scores for atrial fibrillation?
    Roldán V, Marín F, Manzano-Fernandez S, Fernández H, Gallego P, Valdés M, Vicente V, Lip GY.
    Thromb Haemost; 2013 May 12; 109(5):956-60. PubMed ID: 23572113
    [Abstract] [Full Text] [Related]

  • 18. Predictive value of the CHA2DS2-VASc score in atrial fibrillation patients at high risk for stroke despite oral anticoagulation.
    Jover E, Roldán V, Gallego P, Hernández-Romero D, Valdés M, Vicente V, Lip GY, Marín F.
    Rev Esp Cardiol (Engl Ed); 2012 Jul 12; 65(7):627-33. PubMed ID: 22609214
    [Abstract] [Full Text] [Related]

  • 19. Electrocardiographic left ventricular hypertrophy predicts atrial fibrillation independent of left ventricular mass.
    Patel N, O'Neal WT, Whalen SP, Soliman EZ.
    Ann Noninvasive Electrocardiol; 2017 May 12; 22(3):1-5. PubMed ID: 28019050
    [Abstract] [Full Text] [Related]

  • 20. Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study.
    Okin PM, Devereux RB, Gerdts E, Snapinn SM, Harris KE, Jern S, Kjeldsen SE, Julius S, Edelman JM, Lindholm LH, Dahlöf B, LIFE Study Investigators.
    Circulation; 2006 Mar 28; 113(12):1588-96. PubMed ID: 16534012
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.